| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 81 | 2003 | 5866 | 2.130 |
Why?
|
| Prostate-Specific Antigen | 46 | 2003 | 1029 | 1.900 |
Why?
|
| Sarcoma | 30 | 2016 | 1839 | 1.660 |
Why?
|
| Soft Tissue Neoplasms | 14 | 2018 | 927 | 0.940 |
Why?
|
| Adenocarcinoma | 38 | 2003 | 7914 | 0.930 |
Why?
|
| Radiotherapy, Adjuvant | 23 | 2018 | 2271 | 0.840 |
Why?
|
| Neoplasm Recurrence, Local | 58 | 2018 | 10400 | 0.840 |
Why?
|
| Orchiectomy | 15 | 2004 | 211 | 0.800 |
Why?
|
| Skin Neoplasms | 12 | 2013 | 4895 | 0.780 |
Why?
|
| Testicular Neoplasms | 9 | 2004 | 560 | 0.760 |
Why?
|
| Combined Modality Therapy | 67 | 2018 | 9039 | 0.680 |
Why?
|
| Radiotherapy Dosage | 42 | 2015 | 4019 | 0.640 |
Why?
|
| Melanoma | 10 | 2013 | 5595 | 0.600 |
Why?
|
| Radiotherapy, High-Energy | 14 | 2003 | 303 | 0.550 |
Why?
|
| Seminoma | 4 | 2004 | 86 | 0.520 |
Why?
|
| Lymphatic Irradiation | 3 | 2008 | 139 | 0.510 |
Why?
|
| Dysgerminoma | 6 | 1993 | 42 | 0.500 |
Why?
|
| Analysis of Variance | 20 | 2008 | 2315 | 0.500 |
Why?
|
| Aged | 123 | 2018 | 73333 | 0.500 |
Why?
|
| Androgen Antagonists | 6 | 2002 | 420 | 0.480 |
Why?
|
| Actuarial Analysis | 19 | 2004 | 170 | 0.480 |
Why?
|
| Follow-Up Studies | 53 | 2018 | 15218 | 0.470 |
Why?
|
| Middle Aged | 129 | 2018 | 90352 | 0.470 |
Why?
|
| Lymphatic Metastasis | 23 | 2011 | 4963 | 0.470 |
Why?
|
| Male | 160 | 2018 | 128315 | 0.470 |
Why?
|
| Aged, 80 and over | 63 | 2018 | 30998 | 0.460 |
Why?
|
| Dermatofibrosarcoma | 2 | 2013 | 73 | 0.450 |
Why?
|
| Prognosis | 63 | 2018 | 22505 | 0.420 |
Why?
|
| Disease-Free Survival | 23 | 2018 | 10265 | 0.370 |
Why?
|
| Neoplasm Staging | 46 | 2018 | 14012 | 0.370 |
Why?
|
| Adult | 90 | 2018 | 82040 | 0.360 |
Why?
|
| Treatment Outcome | 51 | 2018 | 33737 | 0.340 |
Why?
|
| Humans | 178 | 2018 | 270740 | 0.330 |
Why?
|
| Phyllodes Tumor | 3 | 2000 | 64 | 0.330 |
Why?
|
| Survival Rate | 33 | 2018 | 12541 | 0.330 |
Why?
|
| Retrospective Studies | 57 | 2018 | 39890 | 0.330 |
Why?
|
| Dose-Response Relationship, Radiation | 14 | 2004 | 751 | 0.330 |
Why?
|
| Testosterone | 4 | 1998 | 638 | 0.330 |
Why?
|
| Salvage Therapy | 8 | 2018 | 2123 | 0.310 |
Why?
|
| Reoperation | 2 | 2003 | 1392 | 0.310 |
Why?
|
| Time Factors | 34 | 2008 | 13006 | 0.280 |
Why?
|
| Head and Neck Neoplasms | 3 | 2013 | 4147 | 0.280 |
Why?
|
| Biomarkers, Tumor | 18 | 2003 | 10708 | 0.270 |
Why?
|
| Adolescent | 44 | 2018 | 32767 | 0.260 |
Why?
|
| Lymph Node Excision | 7 | 2011 | 2062 | 0.250 |
Why?
|
| Carcinoma, Transitional Cell | 9 | 1997 | 999 | 0.230 |
Why?
|
| Lower Extremity | 3 | 2016 | 280 | 0.230 |
Why?
|
| Multivariate Analysis | 17 | 2010 | 4328 | 0.230 |
Why?
|
| Radiotherapy | 13 | 2018 | 1857 | 0.220 |
Why?
|
| Retroperitoneal Neoplasms | 4 | 2015 | 296 | 0.220 |
Why?
|
| Female | 76 | 2018 | 148940 | 0.210 |
Why?
|
| Neoplasm Metastasis | 18 | 2009 | 5315 | 0.210 |
Why?
|
| Urinary Bladder Neoplasms | 11 | 1997 | 2431 | 0.210 |
Why?
|
| Fibromatosis, Aggressive | 4 | 2008 | 110 | 0.210 |
Why?
|
| Radiation Injuries | 9 | 2008 | 1471 | 0.210 |
Why?
|
| Sarcoma, Synovial | 3 | 2007 | 141 | 0.210 |
Why?
|
| Organ Sparing Treatments | 2 | 2015 | 283 | 0.190 |
Why?
|
| Survival Analysis | 20 | 2018 | 9292 | 0.180 |
Why?
|
| Histiocytoma, Benign Fibrous | 3 | 2001 | 74 | 0.180 |
Why?
|
| Acid Phosphatase | 7 | 1999 | 56 | 0.180 |
Why?
|
| Ploidies | 5 | 1999 | 250 | 0.170 |
Why?
|
| Extremities | 5 | 2007 | 311 | 0.170 |
Why?
|
| Liposarcoma | 3 | 2015 | 248 | 0.170 |
Why?
|
| Regression Analysis | 9 | 2007 | 1571 | 0.170 |
Why?
|
| Prostatectomy | 10 | 1999 | 1003 | 0.160 |
Why?
|
| Androgens | 1 | 2001 | 506 | 0.150 |
Why?
|
| Neurofibrosarcoma | 1 | 2018 | 42 | 0.150 |
Why?
|
| Child | 25 | 2015 | 30559 | 0.150 |
Why?
|
| Prostate | 7 | 2002 | 1089 | 0.150 |
Why?
|
| Solitary Fibrous Tumors | 1 | 2018 | 48 | 0.140 |
Why?
|
| Cystectomy | 8 | 1997 | 635 | 0.140 |
Why?
|
| Young Adult | 8 | 2018 | 22251 | 0.140 |
Why?
|
| DNA, Neoplasm | 4 | 1999 | 1958 | 0.130 |
Why?
|
| Limb Salvage | 2 | 2015 | 162 | 0.130 |
Why?
|
| Femoral Fractures | 1 | 2016 | 66 | 0.130 |
Why?
|
| Bone Neoplasms | 6 | 2015 | 2665 | 0.130 |
Why?
|
| Child, Preschool | 12 | 2008 | 17061 | 0.130 |
Why?
|
| Hand Bones | 1 | 2015 | 8 | 0.130 |
Why?
|
| Testis | 1 | 1998 | 620 | 0.120 |
Why?
|
| Foot Diseases | 1 | 2015 | 47 | 0.120 |
Why?
|
| Surgical Procedures, Operative | 1 | 2018 | 359 | 0.120 |
Why?
|
| Chemotherapy, Adjuvant | 6 | 2006 | 4000 | 0.120 |
Why?
|
| Antigens, Neoplasm | 2 | 1992 | 1580 | 0.120 |
Why?
|
| Texas | 5 | 2018 | 6449 | 0.120 |
Why?
|
| Misonidazole | 2 | 1985 | 11 | 0.120 |
Why?
|
| Recurrence | 6 | 2001 | 4878 | 0.110 |
Why?
|
| Clinical Trials as Topic | 6 | 2009 | 3844 | 0.110 |
Why?
|
| Anus Neoplasms | 2 | 2011 | 414 | 0.110 |
Why?
|
| Liposarcoma, Myxoid | 2 | 2007 | 38 | 0.110 |
Why?
|
| Diethylstilbestrol | 2 | 1995 | 165 | 0.110 |
Why?
|
| Cohort Studies | 12 | 2018 | 9470 | 0.110 |
Why?
|
| Gonadotropin-Releasing Hormone | 3 | 1999 | 169 | 0.100 |
Why?
|
| Kinetics | 5 | 1997 | 2220 | 0.100 |
Why?
|
| Urinary Bladder | 4 | 2000 | 593 | 0.100 |
Why?
|
| Cryptorchidism | 1 | 1992 | 49 | 0.100 |
Why?
|
| Doxorubicin | 5 | 2004 | 3145 | 0.100 |
Why?
|
| Radiotherapy, Conformal | 4 | 2000 | 898 | 0.090 |
Why?
|
| Preoperative Care | 4 | 2006 | 1567 | 0.090 |
Why?
|
| Radiography | 3 | 2008 | 1986 | 0.090 |
Why?
|
| Ki-67 Antigen | 3 | 2003 | 675 | 0.090 |
Why?
|
| Age Factors | 6 | 2018 | 5457 | 0.090 |
Why?
|
| Treatment Failure | 6 | 2007 | 1430 | 0.090 |
Why?
|
| Anal Canal | 1 | 2011 | 236 | 0.090 |
Why?
|
| Facial Neoplasms | 1 | 2010 | 77 | 0.090 |
Why?
|
| Lymph Nodes | 3 | 2011 | 3077 | 0.090 |
Why?
|
| Jaw Neoplasms | 1 | 2009 | 17 | 0.080 |
Why?
|
| Tumor Burden | 2 | 2013 | 2033 | 0.080 |
Why?
|
| Scalp | 1 | 2010 | 155 | 0.080 |
Why?
|
| Antibiotics, Antineoplastic | 3 | 2004 | 742 | 0.080 |
Why?
|
| Thoracic Neoplasms | 2 | 2007 | 363 | 0.080 |
Why?
|
| Rectal Neoplasms | 2 | 2011 | 1240 | 0.080 |
Why?
|
| Osteosarcoma | 2 | 2009 | 950 | 0.080 |
Why?
|
| Hodgkin Disease | 3 | 1986 | 1485 | 0.080 |
Why?
|
| Hemangiosarcoma | 1 | 2010 | 238 | 0.070 |
Why?
|
| Quality of Health Care | 1 | 2012 | 618 | 0.070 |
Why?
|
| Axilla | 2 | 2008 | 939 | 0.070 |
Why?
|
| Laparotomy | 2 | 1985 | 235 | 0.070 |
Why?
|
| Surveys and Questionnaires | 2 | 2003 | 5923 | 0.070 |
Why?
|
| Postoperative Period | 2 | 2003 | 666 | 0.070 |
Why?
|
| Bone Marrow Transplantation | 5 | 1994 | 1757 | 0.070 |
Why?
|
| Periosteum | 1 | 2007 | 46 | 0.070 |
Why?
|
| Postoperative Care | 1 | 2010 | 728 | 0.070 |
Why?
|
| Retinoblastoma Protein | 2 | 1997 | 339 | 0.070 |
Why?
|
| Infant | 6 | 2004 | 13999 | 0.070 |
Why?
|
| Cancer Care Facilities | 2 | 2018 | 907 | 0.060 |
Why?
|
| Abdominal Neoplasms | 1 | 1988 | 251 | 0.060 |
Why?
|
| Retreatment | 1 | 2007 | 448 | 0.060 |
Why?
|
| Diploidy | 2 | 1997 | 116 | 0.060 |
Why?
|
| Medical Records | 2 | 2006 | 442 | 0.060 |
Why?
|
| Breast Neoplasms | 4 | 2000 | 16215 | 0.060 |
Why?
|
| Risk Factors | 4 | 2016 | 17888 | 0.060 |
Why?
|
| Neoplasm Invasiveness | 9 | 2018 | 4048 | 0.060 |
Why?
|
| Brachytherapy | 4 | 2007 | 1005 | 0.060 |
Why?
|
| Apoptosis | 5 | 2000 | 7757 | 0.060 |
Why?
|
| Proportional Hazards Models | 8 | 2002 | 5101 | 0.060 |
Why?
|
| Life Tables | 1 | 2003 | 120 | 0.050 |
Why?
|
| Neoplasm, Residual | 4 | 2015 | 1754 | 0.050 |
Why?
|
| Giant Cell Tumor of Bone | 1 | 2003 | 53 | 0.050 |
Why?
|
| Ultrasonography | 4 | 2000 | 1933 | 0.050 |
Why?
|
| Hand | 2 | 2002 | 175 | 0.050 |
Why?
|
| Biopsy, Needle | 2 | 1998 | 1379 | 0.050 |
Why?
|
| S Phase | 3 | 1999 | 288 | 0.050 |
Why?
|
| Surgical Wound Infection | 1 | 2006 | 495 | 0.050 |
Why?
|
| Prospective Studies | 8 | 2007 | 13414 | 0.050 |
Why?
|
| Half-Life | 2 | 1997 | 269 | 0.050 |
Why?
|
| Biopsy | 4 | 2012 | 3484 | 0.050 |
Why?
|
| Rhabdomyosarcoma | 2 | 2002 | 342 | 0.050 |
Why?
|
| Spermatic Cord | 1 | 2001 | 18 | 0.050 |
Why?
|
| Erectile Dysfunction | 3 | 2003 | 239 | 0.050 |
Why?
|
| Genital Neoplasms, Male | 1 | 2001 | 44 | 0.050 |
Why?
|
| Nitroimidazoles | 1 | 1982 | 107 | 0.050 |
Why?
|
| Continuity of Patient Care | 1 | 2003 | 206 | 0.050 |
Why?
|
| Rectum | 2 | 2000 | 480 | 0.050 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2003 | 500 | 0.050 |
Why?
|
| Urination Disorders | 2 | 1998 | 63 | 0.050 |
Why?
|
| Radiation-Sensitizing Agents | 2 | 1985 | 368 | 0.050 |
Why?
|
| Ifosfamide | 1 | 2001 | 358 | 0.050 |
Why?
|
| Minisatellite Repeats | 1 | 2000 | 66 | 0.050 |
Why?
|
| Cause of Death | 1 | 2004 | 789 | 0.050 |
Why?
|
| Mediastinum | 1 | 2001 | 276 | 0.040 |
Why?
|
| Abdomen | 1 | 2001 | 347 | 0.040 |
Why?
|
| Incidence | 3 | 2001 | 5824 | 0.040 |
Why?
|
| Palpation | 2 | 2000 | 51 | 0.040 |
Why?
|
| Predictive Value of Tests | 6 | 2002 | 4960 | 0.040 |
Why?
|
| Seminal Vesicles | 1 | 1998 | 149 | 0.040 |
Why?
|
| Dihydrotestosterone | 1 | 1998 | 94 | 0.040 |
Why?
|
| Fibrosis | 1 | 2001 | 733 | 0.040 |
Why?
|
| Luteinizing Hormone | 1 | 1998 | 165 | 0.040 |
Why?
|
| Patient Satisfaction | 1 | 2003 | 917 | 0.040 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2001 | 605 | 0.040 |
Why?
|
| Heart Diseases | 1 | 2004 | 724 | 0.040 |
Why?
|
| Genes, Retinoblastoma | 1 | 1997 | 92 | 0.040 |
Why?
|
| Carcinoma | 2 | 2003 | 2610 | 0.040 |
Why?
|
| Intestinal Diseases | 1 | 1998 | 125 | 0.040 |
Why?
|
| Polyploidy | 1 | 1997 | 76 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2003 | 2650 | 0.030 |
Why?
|
| Melphalan | 3 | 1990 | 879 | 0.030 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 1997 | 347 | 0.030 |
Why?
|
| Aneuploidy | 1 | 1997 | 382 | 0.030 |
Why?
|
| Endosonography | 1 | 1999 | 551 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2018 | 984 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2003 | 1542 | 0.030 |
Why?
|
| Hematuria | 2 | 2003 | 83 | 0.030 |
Why?
|
| Neoplasms, Second Primary | 1 | 2004 | 1388 | 0.030 |
Why?
|
| Hand Dermatoses | 1 | 2015 | 27 | 0.030 |
Why?
|
| Foot Dermatoses | 1 | 2015 | 25 | 0.030 |
Why?
|
| Vaginal Neoplasms | 1 | 1996 | 152 | 0.030 |
Why?
|
| Movement | 1 | 1998 | 556 | 0.030 |
Why?
|
| Muscle Neoplasms | 1 | 1996 | 108 | 0.030 |
Why?
|
| Flutamide | 1 | 1995 | 45 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2018 | 6256 | 0.030 |
Why?
|
| Whole-Body Irradiation | 4 | 1994 | 323 | 0.030 |
Why?
|
| Radiodermatitis | 1 | 2015 | 79 | 0.030 |
Why?
|
| Mass Screening | 1 | 2003 | 1552 | 0.030 |
Why?
|
| Neutrons | 1 | 1995 | 117 | 0.030 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 1997 | 3658 | 0.030 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 1999 | 841 | 0.030 |
Why?
|
| Linear Models | 1 | 1997 | 1093 | 0.030 |
Why?
|
| Mastectomy | 1 | 2000 | 1553 | 0.030 |
Why?
|
| Drug Evaluation | 2 | 1985 | 432 | 0.030 |
Why?
|
| Chorionic Gonadotropin, beta Subunit, Human | 1 | 1993 | 56 | 0.030 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 1996 | 5593 | 0.030 |
Why?
|
| Urethral Neoplasms | 1 | 1993 | 62 | 0.030 |
Why?
|
| Chorionic Gonadotropin | 1 | 1993 | 127 | 0.030 |
Why?
|
| Probability | 1 | 1995 | 886 | 0.030 |
Why?
|
| Sex Factors | 1 | 2018 | 2184 | 0.030 |
Why?
|
| Flow Cytometry | 5 | 1997 | 3045 | 0.030 |
Why?
|
| Pelvis | 3 | 2004 | 381 | 0.030 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 3 | 1999 | 2457 | 0.030 |
Why?
|
| Forecasting | 1 | 1994 | 702 | 0.020 |
Why?
|
| Piperazines | 2 | 1994 | 2145 | 0.020 |
Why?
|
| Wound Healing | 2 | 2006 | 749 | 0.020 |
Why?
|
| Immunohistochemistry | 5 | 2003 | 7655 | 0.020 |
Why?
|
| Logistic Models | 1 | 1998 | 3444 | 0.020 |
Why?
|
| Statistics as Topic | 3 | 2004 | 453 | 0.020 |
Why?
|
| Muscle, Smooth | 3 | 1997 | 251 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2018 | 2250 | 0.020 |
Why?
|
| Genes, p53 | 1 | 1995 | 1140 | 0.020 |
Why?
|
| Cyclosporins | 1 | 1990 | 111 | 0.020 |
Why?
|
| DNA | 2 | 2000 | 3050 | 0.020 |
Why?
|
| Cisplatin | 2 | 1988 | 2497 | 0.020 |
Why?
|
| Fibroma | 1 | 1990 | 86 | 0.020 |
Why?
|
| Rectal Diseases | 3 | 1996 | 57 | 0.020 |
Why?
|
| Methylprednisolone | 1 | 1990 | 198 | 0.020 |
Why?
|
| Amifostine | 2 | 1986 | 99 | 0.020 |
Why?
|
| Quality of Life | 1 | 2003 | 4761 | 0.020 |
Why?
|
| SEER Program | 1 | 2012 | 1047 | 0.020 |
Why?
|
| Splenectomy | 2 | 1986 | 168 | 0.020 |
Why?
|
| Proctitis | 1 | 1987 | 18 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2002 | 16689 | 0.020 |
Why?
|
| Urination | 1 | 1987 | 33 | 0.020 |
Why?
|
| Mutation | 2 | 2000 | 15912 | 0.020 |
Why?
|
| Neovascularization, Pathologic | 1 | 1994 | 1586 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 1993 | 1309 | 0.020 |
Why?
|
| Disease Progression | 2 | 1997 | 6867 | 0.020 |
Why?
|
| Stochastic Processes | 1 | 1987 | 51 | 0.020 |
Why?
|
| Leukocyte Count | 2 | 1986 | 735 | 0.020 |
Why?
|
| Multiple Myeloma | 2 | 1990 | 2328 | 0.020 |
Why?
|
| Medicare | 1 | 2012 | 926 | 0.020 |
Why?
|
| Organothiophosphorus Compounds | 1 | 1986 | 6 | 0.020 |
Why?
|
| Random Allocation | 1 | 1988 | 741 | 0.020 |
Why?
|
| Cystitis | 1 | 1987 | 109 | 0.020 |
Why?
|
| Methotrexate | 1 | 1990 | 1025 | 0.020 |
Why?
|
| Radiation Protection | 1 | 1987 | 204 | 0.020 |
Why?
|
| Neoplasms | 3 | 1987 | 15927 | 0.020 |
Why?
|
| Infusions, Intravenous | 2 | 2004 | 1437 | 0.020 |
Why?
|
| Radiation-Protective Agents | 1 | 1986 | 129 | 0.020 |
Why?
|
| Pelvic Neoplasms | 1 | 1987 | 199 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 1997 | 3345 | 0.020 |
Why?
|
| Biomarkers | 1 | 1997 | 5051 | 0.020 |
Why?
|
| Sex Characteristics | 1 | 2008 | 425 | 0.020 |
Why?
|
| Microsurgery | 1 | 2007 | 235 | 0.020 |
Why?
|
| Creatinine | 1 | 1987 | 529 | 0.020 |
Why?
|
| Neoplasm Transplantation | 2 | 2000 | 1553 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2018 | 6764 | 0.020 |
Why?
|
| Clinical Protocols | 1 | 2007 | 477 | 0.020 |
Why?
|
| Rats | 3 | 2000 | 6441 | 0.020 |
Why?
|
| Cell Division | 2 | 2000 | 2657 | 0.010 |
Why?
|
| Spinal Cord | 1 | 1987 | 718 | 0.010 |
Why?
|
| Fractures, Bone | 1 | 2006 | 310 | 0.010 |
Why?
|
| Pain, Intractable | 1 | 1985 | 180 | 0.010 |
Why?
|
| Nausea | 1 | 1985 | 539 | 0.010 |
Why?
|
| bcl-X Protein | 1 | 2003 | 198 | 0.010 |
Why?
|
| Necrosis | 1 | 2004 | 595 | 0.010 |
Why?
|
| Urinary Incontinence | 1 | 2003 | 148 | 0.010 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2003 | 374 | 0.010 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 1994 | 2635 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 1993 | 4116 | 0.010 |
Why?
|
| Cell Count | 2 | 1997 | 512 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2007 | 2057 | 0.010 |
Why?
|
| Intraoperative Care | 1 | 2003 | 274 | 0.010 |
Why?
|
| Lymphoma | 2 | 1987 | 1519 | 0.010 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2003 | 200 | 0.010 |
Why?
|
| Bone Marrow | 2 | 1986 | 2441 | 0.010 |
Why?
|
| Lymphedema | 1 | 2004 | 239 | 0.010 |
Why?
|
| Arm | 1 | 2002 | 139 | 0.010 |
Why?
|
| Graft vs Host Disease | 2 | 1990 | 2810 | 0.010 |
Why?
|
| Administration, Oral | 1 | 1985 | 1608 | 0.010 |
Why?
|
| Leukemia, Myeloid | 1 | 1986 | 993 | 0.010 |
Why?
|
| United States | 2 | 2012 | 15861 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 1982 | 591 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 2 | 2000 | 5759 | 0.010 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 1986 | 625 | 0.010 |
Why?
|
| Cell Survival | 1 | 1987 | 3063 | 0.010 |
Why?
|
| Maximum Tolerated Dose | 1 | 2004 | 1322 | 0.010 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2003 | 334 | 0.010 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 1994 | 2903 | 0.010 |
Why?
|
| Edema | 1 | 2002 | 262 | 0.010 |
Why?
|
| Diarrhea | 1 | 2003 | 716 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2002 | 1312 | 0.010 |
Why?
|
| Cyclophosphamide | 1 | 1987 | 3245 | 0.010 |
Why?
|
| Models, Biological | 1 | 1987 | 3194 | 0.010 |
Why?
|
| Nervous System Diseases | 1 | 1982 | 517 | 0.010 |
Why?
|
| Sarcoma, Ewing | 1 | 2001 | 428 | 0.010 |
Why?
|
| Castration | 1 | 1997 | 122 | 0.010 |
Why?
|
| Patient Care Planning | 1 | 1999 | 303 | 0.010 |
Why?
|
| Palliative Care | 3 | 1986 | 2178 | 0.010 |
Why?
|
| Mitotic Index | 1 | 1997 | 162 | 0.010 |
Why?
|
| Radioisotope Teletherapy | 1 | 1996 | 11 | 0.010 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 1999 | 232 | 0.010 |
Why?
|
| Inguinal Canal | 1 | 1996 | 64 | 0.010 |
Why?
|
| Ultrasonography, Interventional | 1 | 1999 | 424 | 0.010 |
Why?
|
| Urinary Bladder Diseases | 1 | 1996 | 53 | 0.010 |
Why?
|
| Diagnostic Imaging | 1 | 2003 | 1174 | 0.010 |
Why?
|
| Platelet Count | 2 | 1986 | 492 | 0.010 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 1994 | 7265 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2000 | 3476 | 0.010 |
Why?
|
| Pilot Projects | 2 | 1994 | 2828 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2009 | 5681 | 0.010 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2003 | 2617 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2003 | 2400 | 0.010 |
Why?
|
| Hemoglobins | 1 | 1995 | 482 | 0.010 |
Why?
|
| Multicenter Studies as Topic | 1 | 1994 | 558 | 0.010 |
Why?
|
| von Willebrand Factor | 1 | 1994 | 246 | 0.010 |
Why?
|
| Radiation Dosage | 1 | 1997 | 1042 | 0.010 |
Why?
|
| Antineoplastic Agents | 3 | 2010 | 14617 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2002 | 4372 | 0.010 |
Why?
|
| Genetic Markers | 1 | 1994 | 1075 | 0.010 |
Why?
|
| Wrist | 1 | 1990 | 28 | 0.010 |
Why?
|
| Urologic Diseases | 1 | 1991 | 83 | 0.010 |
Why?
|
| Ankle | 1 | 1990 | 37 | 0.010 |
Why?
|
| Neoadjuvant Therapy | 1 | 2004 | 5231 | 0.010 |
Why?
|
| Foot | 1 | 1990 | 94 | 0.010 |
Why?
|
| Liver Neoplasms | 1 | 2007 | 4821 | 0.010 |
Why?
|
| Lung Neoplasms | 3 | 2007 | 12033 | 0.010 |
Why?
|
| Animals | 3 | 2000 | 61956 | 0.010 |
Why?
|
| Base Sequence | 1 | 1995 | 5437 | 0.000 |
Why?
|
| Cobalt Radioisotopes | 1 | 1987 | 41 | 0.000 |
Why?
|
| Clavicle | 1 | 1987 | 68 | 0.000 |
Why?
|
| Prednisone | 1 | 1990 | 1034 | 0.000 |
Why?
|
| Molecular Sequence Data | 1 | 1995 | 6685 | 0.000 |
Why?
|
| Mathematics | 1 | 1987 | 141 | 0.000 |
Why?
|
| Blood Cells | 1 | 1987 | 129 | 0.000 |
Why?
|
| Algorithms | 1 | 1998 | 3891 | 0.000 |
Why?
|
| Bone and Bones | 1 | 1990 | 605 | 0.000 |
Why?
|
| Preservation, Biological | 1 | 1986 | 15 | 0.000 |
Why?
|
| Freezing | 1 | 1986 | 62 | 0.000 |
Why?
|
| Vincristine | 1 | 1990 | 1583 | 0.000 |
Why?
|
| Electrons | 1 | 1987 | 188 | 0.000 |
Why?
|
| Intestines | 1 | 1990 | 736 | 0.000 |
Why?
|
| Granulocytes | 1 | 1986 | 244 | 0.000 |
Why?
|
| Transplantation, Autologous | 1 | 1990 | 2067 | 0.000 |
Why?
|
| Dexamethasone | 1 | 1990 | 1516 | 0.000 |
Why?
|
| Premedication | 1 | 1985 | 133 | 0.000 |
Why?
|
| Drug Therapy, Combination | 1 | 1990 | 2345 | 0.000 |
Why?
|
| Karyotyping | 1 | 1986 | 1063 | 0.000 |
Why?
|
| Disease Models, Animal | 1 | 1997 | 7381 | 0.000 |
Why?
|
| Carcinoma, Small Cell | 1 | 1985 | 427 | 0.000 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 1990 | 5056 | 0.000 |
Why?
|
| Tomography, X-Ray Computed | 1 | 1998 | 7783 | 0.000 |
Why?
|
| Philadelphia Chromosome | 1 | 1986 | 852 | 0.000 |
Why?
|
| Risk | 1 | 1986 | 1939 | 0.000 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 1997 | 9042 | 0.000 |
Why?
|
| Cell Cycle | 1 | 1987 | 2137 | 0.000 |
Why?
|
| Hematopoietic Stem Cells | 1 | 1986 | 1367 | 0.000 |
Why?
|